Why India Must Urgently Reinvent Healthcare for a 100-Year...

In the lockdown, while I was on regular OPD and ICU rounds at a COVID hospital, I started noticing some mild symptoms of the Coronavirus infection. Being in the medical field and considering the severity of the pandemic situation then, I was very careful and cautious, and observed the symptoms closely. The symptoms persisted and I had to self-quarantine until the medical test reports came. It was important for me to isolate myself from the rest of the medical team and prevent the spread of the virus. Finally, the report came: I was COVID positive! Stunned and slightly devastated; I broke the news to my family who could not believe it either. As a doctor, I could only treat, comfort and empathize with the COVID patients undergoing treatment; completely isolated from their loved ones. But now, I could actually feel the uncertainty of the situation. I was hospitalized and continued to experience body-ache during the admission. It was a stressful situation where I felt anxious and stressed about everything. My CT scan reports showed mild lung infection on the day of admission but as the cytokines storm developed, my lungs were 76 % damaged in 3-5 days and I was short of breath and my oxygen level deteriorated to less than 80.  I was shifted to an ICU with high-flow oxygen and was on a BiPap machine which I had purchased a few weeks ago for the hospital and never imagined that I would be using myself one day.

A recent industry spotlight by Venkat Mutavi notes a...

In the dynamic world of pharmaceutical marketing, staying ahead of the curve is essential for success. As technology continues to evolve, so do the opportunities for innovative campaigns. One area where pharma marketers can make a significant impact is in raising awareness about non-communicable diseases (NCDs) and promoting real-world studies and clinical trials.

IPM was valued at Rs. 178,219 Cr for MAT Oct’21. The retail sector was valued at Rs. 151,183 Cr for this period contributing 85% to IPM. IPM Growth for the month of Oct’21 as compared to the month of Oct’20 was 9.7%. This is the lowest monthly growth in the last 8 months after a low growth of 2.6% reported for Feb’21. Corresponding to low monthly growth, IPM MAT growth also declined slightly after showing a growing trend consistently for the last 7 months from MAT Feb’21. It reported 17.3% for MAT Oct’21 as compared to 17.8% reported for MAT Sept’21. At 15657.3 Cr, the monthly sale reported for Oct’21 is the 5th highest sale value in the last 12 months.

When drones first appeared on battlefields, military establishments reacted...

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

From Gas Cylinders to ICU Beds: How the Gulf...

As over 50 generic versions of the blockbuster weight-loss...

Excellence is a choice. So is Mediocrity Excellence is a...

When drones first appeared on battlefields, military establishments reacted...

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

From Gas Cylinders to ICU Beds: How the Gulf...

As over 50 generic versions of the blockbuster weight-loss...

Excellence is a choice. So is Mediocrity Excellence is a...

When drones first appeared on battlefields, military establishments reacted...

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

From Gas Cylinders to ICU Beds: How the Gulf...

As over 50 generic versions of the blockbuster weight-loss...

Excellence is a choice. So is Mediocrity Excellence is a...

When drones first appeared on battlefields, military establishments reacted...

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

From Gas Cylinders to ICU Beds: How the Gulf...

As over 50 generic versions of the blockbuster weight-loss...

Excellence is a choice. So is Mediocrity Excellence is a...